InnovAge Holding Corp. Announces 10M-Share Secondary Offering

What Happened

• InnovAge Holding Corp. filed an 8-K disclosing that on September 22, 2026 it entered into an underwriting agreement with a selling shareholder and representatives of the underwriters (Barclays Capital Inc., Goldman Sachs & Co. LLC and Wells Fargo Securities, LLC). The selling shareholder agreed to sell 10,000,000 shares of the company’s common stock at $9.25 per share. The selling shareholder also granted the underwriters a 30‑day option to buy up to an additional 1,500,000 shares. The offering was registered on the company’s Form S-3 and the Shares were delivered against payment on September 24, 2026. The Company will not receive any proceeds from the sale.

Key Details

• Firm Shares: 10,000,000 shares sold at $9.25 per share.
• Overallotment Option: Underwriters may buy up to 1,500,000 additional shares for 30 days (through Oct. 22, 2026).
• Underwriters: Barclays Capital Inc., Goldman Sachs & Co. LLC and Wells Fargo Securities, LLC.
• Company Impact: The offering involves existing shares held by a selling shareholder; InnovAge receives no proceeds and did not issue new shares in this transaction.

Why It Matters

• This was a secondary sale by a shareholder, not a capital raise by InnovAge, so the company did not receive cash and the transaction did not increase shares outstanding (i.e., not dilutive via new issuance).
• The transaction increases the number of shares available for public trading and the underwriters’ over-allotment option could add up to 15% more shares sold, which investors should note as potential additional supply.
• The underwriting agreement includes customary representations, covenants and indemnities; the filing attaches the agreement as Exhibit 1.1 for full terms.